There were no significant differences between non-relapsing and relapsing groups in any other clinical characteristics, including patient’s age, alloHSCT, secondary AML, extramedullary disease, normal karyotype, NPM1 mutation and FLT3-ITD gene fusion. This evidence concerns the gene FLT3 and acute myeloid leukemia.